The European Medicines Agency has requested an addition to AstraZeneca’s COVID vaccine label.


The European Medicines Agency has requested an addition to AstraZeneca’s COVID vaccine label.

The European Union’s (EU) medicines authority has requested that AstraZeneca’s COVID-19 vaccination label be amended to include a warning concerning a capillary leak condition side effect, according to the agency.

Six persons who took the AstraZeneca dose and afterwards had the rare capillary leak condition were investigated by the European Medicines Agency (EMA). The EMA wants AstraZeneca’s label to include the side effect.

Meanwhile, the FDA is still looking into the limited number of persons who had heart inflammation after getting the Pfizer-BioNTech or Moderna vaccination. The EMA stated, “Further analysis is needed to evaluate whether there is a causal relation with the vaccinations.”

AstraZeneca’s vaccine has already been related to rare blood clots. However, health officials claim that the benefits of having the shot exceed the risks.

See the following links for further Associated Press reporting:

The European Medicines Agency (EMA) has approved a new manufacturing location for the Moderna COVID-19 vaccine, which could significantly increase EU output.

The European Medicines Agency (EMA) announced on Friday that it has approved a Recipharm plant in Monts, France. The EMA also approved six other sites to conduct batch control and testing, in addition to the new site.

Two locations in the United States were approved this month for the manufacturing of vaccinations for the EU’s 27-nation union. The EMA must first approve the production facilities for any medicines or vaccines that are licensed for the EU market.

According to the EMA, these newly approved locations will result in an additional 1 million to 2 million vials of Moderna’s coronavirus vaccine being produced each month.

The EMA says it’s recommending that people who have had a rare blood vessel syndrome not be immunized with AstraZeneca’s COVID-19 vaccine.

The EMA also said it is studying cases of myocarditis, inflammation of the heart, and pericarditis, inflammation of the membrane surrounding the heart. Symptoms include shortness of breath and chest pain; the problems are usually temporary.

The EMA said it expects to finalize its review of such cases next month.

Europe, alongside the rest of the world, continues to deal with the COVID-19 pandemic.

Germany is lifting a blanket travel warning for countries with high coronavirus infection rates starting July 1.

Foreign Minister Heiko Maas says that “after many months of lockdown, we can look forward to. This is a brief summary.


Leave A Reply